Immunovant
Announced 21 Jan 2026$1.5B · Series C · Hospitals and Health Care · United States
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases.
“Significant capital flowed into targeted protein degradation, RNA modalities, and AI-driven genomics to close out the year. M&A: Stago entered exclusive negotiations to sell a majority stake to private equity firm ARCHIMED to accelerate the adoption of its coagulation platforms.”